Abstract
This chapter reviews what is known about the therapeutic uses of the serotonergic or classic hallucinogens, i.e., psychoactive drugs such as LSD and psilocybin that exert their effects primarily through agonist activity at serotonin 2A (5HT2A) receptors. Following a review of the history of human use and scientific study of these drugs, the data from clinical research are summarized, including extensive work on the use of classic hallucinogens in the treatment of alcoholism and other addictions, studies of the use of LSD and psilocybin to relieve distress concerning death, particularly in patients with advanced or terminal cancer, and more limited data concerning the use of classic hallucinogens to treat mood and anxiety disorders. A survey of possible mechanisms of clinically relevant effects is provided. The well-established safety of classic hallucinogens is reviewed. To provide a clinical perspective, case summaries are provided of two individuals who received treatment in recent controlled trials of psilocybin: one being treated for alcoholism, the other suffering from anxiety and depression related to fear of death due to a cancer diagnosis. Although promising early phase research conducted from the 1950s through the earl...Continue Reading
Citations
Aug 14, 2018·International Review of Psychiatry·Stephen Ross
Jul 16, 2019·Journal of Psychopharmacology·Kim Pc KuypersDavid Nutt
Feb 23, 2020·PloS One·Bheatrix BienemannDaniel C Mograbi
Dec 20, 2019·Pain Management·Saibal Das, Tanay Maiti
Feb 27, 2020·The American Journal of Psychiatry·Collin M ReiffUNKNOWN the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research
Jul 27, 2020·Chronic Stress·Alan K DavisTimothy Amoroso
Jan 10, 2021·Psychopharmacology·C J Healy
Jan 12, 2021·Psychopharmacology·Nicole L Galvão-CoelhoJerome Sarris
Jan 21, 2021·Pharmacopsychiatry·Lea J Mertens, Katrin H Preller
Jan 23, 2021·Scientific Reports·April ContrerasDustin J Hines
Apr 3, 2019·Reviews in the Neurosciences·Noemi Császár-NagyIstván Bókkon
Dec 22, 2020·Frontiers in Pharmacology·Daniela DudysováJiří Horáček
Mar 13, 2021·Risk Management and Healthcare Policy·Rafael Guimarães Dos SantosJaime E Hallak
Apr 17, 2021·ACS Pharmacology & Translational Science·Eline PottieChristophe P Stove
Apr 17, 2021·ACS Pharmacology & Translational Science·Adam K KleinAdam L Halberstadt
Apr 17, 2021·ACS Pharmacology & Translational Science·Stephen RossSarah E Mennenga
Apr 29, 2021·ACS Chemical Neuroscience·Eline PottieChristophe P Stove
Dec 7, 2019·Neuroscience and Biobehavioral Reviews·Rafael Guimarães Dos Santos, Jaime Eduardo Cecilio Hallak
May 19, 2021·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Wayne Hall
May 26, 2021·Psychopharmacology·Monika HerianKrystyna Gołembiowska
Jul 31, 2021·Frontiers in Psychology·Sascha B ThalPetra M Skeffington
Jul 14, 2021·Cerebral Cortex·Patricia DuerlerKatrin H Preller
Nov 15, 2019·Analytical Chemistry·Eline PottieChristophe P Stove
Oct 5, 2021·Frontiers in Pharmacology·Lukas A BasedowTomislav Majić
Oct 1, 2020·Biochemical Pharmacology·Eline PottieChristophe P Stove